Gene Im, MD
img_Gene Im
ASSOCIATE PROFESSOR | Medicine, Liver Diseases
Are you a patient?
Specialties
Internal Medicine, Gastroenterology, Liver Transplantation
Research Topics
Addiction, Health Services Research, Hepatitis C Virus, Liver, Transplantation
Outcomes of Inpatient Hospital Transfers to a Liver Transplant Center
The purpose of this study is to examine the characteristics and outcomes of patients referred for inpatient hospital transfer to Mount Sinai Medical Center. These patients anecdotally have poor clinical outcomes, but a systematic evaluation of this special population has not been performed. Multivariate analysis demonstrated that patients with acute on chronic liver failure were more likely to have inpatient mortality. Future efforts will focus on a cost analysis of inpatient hospital transfers to the liver service.
Emerging Therapies for Severe Alcoholic Hepatitis

Early liver transplantation for severe alcoholic hepatitis has recently been demonstrated to be a feasible and effective therapy for highly selected patients who fail medical therapy and violate the so-called “6 month rule,” using a rigorous evaluation program. Here at Mount Sinai, we are leading the North American experience of early liver transplantation as a rescue therapy for selected patients with severe alcoholic hepatitis. Particular areas of interest include patient selection, outcomes, burden on organ supply and alcohol relapse. Translational collaborations are being planned with the Alcoholic Liver Disease Research Center at Mount Sinai to further elucidate the pathogenesis of alcoholic hepatitis. Future clinical trials to evaluate therapies with less side-effects, more targeted therapies or those aimed hepatic regeneration are needed.

MD, New York Medical College

Residency, Internal Medicine, Winthrop-University Hospital

Fellowship, Gastroenterology, Winthrop-University Hospital

Fellowship, Transplant Hepatology, Mount Sinai Hospital

Certifications

American Board of Internal Medicine
Early Liver Transplantation for Severe Alcoholic Hepatitis

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Im has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.